Sugi Predict

Sugi Predict / Compounds / SCHEMBL25397998

SCHEMBL25397998

SCHEMBL25397998

COc1ccc(C(O[C@H]2[C@H](F)[C@H](n3cc(F)c(=O)[nH]c3=O)O[C@@H]2C=O)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.44
▸ LMNA P02545 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ PMP22 Q01453 1/20 0.37
▸ HBB P68871 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TYMP P19971 1/20 0.35
▸ TK2 O00142 2/20 0.33
▸ P2RY6 Q15077 2/20 0.33
▸ P2RY14 Q15391 2/20 0.33
▸ NT5E P21589 1/20 0.33
▸ TYMS P04818 2/20 0.32
▸ SERPINE1 P05121 1/20 0.31
▸ TK1 P04183 2/20 0.30
▸ ESR1 P03372 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25397635 0.91 TK2 (0.38) HSP90AA1TYMPTK2TK1
SCHEMBL25402034 0.91 TK2 (0.38) HSP90AA1TYMPTK2TK1
SCHEMBL25399269 0.91 HSP90AA1 (0.43) HSP90AA1LMNAMAPTTSHRPMP22
SCHEMBL25399357 0.86 P2RY14 (0.38) TYMPP2RY6P2RY14NT5E
SCHEMBL25400695 0.85 HSP90AA1 (0.43) HSP90AA1LMNAMAPTTSHRPMP22
SCHEMBL25400583 0.83 HSP90AA1 (0.42) HSP90AA1LMNAMAPTTSHRPMP22
SCHEMBL30670589 0.82 HSP90AA1 (0.45) HSP90AA1LMNAMAPTSMN1; SMN2TYMP
SCHEMBL25398942 0.78 HSP90AA1 (0.43) HSP90AA1LMNAMAPTTSHRPMP22
SCHEMBL25403441 0.77 TYMP (0.44) LMNATYMPTK2
SCHEMBL25400439 0.77 TYMP (0.44) LMNATYMPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145654-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2025-05-08 — — US disclosed
EP-4493573-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE Rome Therapeutics, Inc. (US) 2025-01-22 — — EP disclosed
US-12187758-B2 Compounds and methods for treating disease ROME THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2023-11-23 — — US disclosed
WO-2023178133-A9 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. (US) 2023-10-26 — — WO disclosed
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS INC (US) 2023-09-21 — — US disclosed
WO-2023178133-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 HSP90AA1 2000/4885LMNA 2032/4885MAPT 147/4885
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 HSP90AA1 2000/4885LMNA 2032/4885MAPT 147/4885
US-20250145654-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 HSP90AA1 2000/4885LMNA 2032/4885MAPT 147/4885
US-12187758-B2 Compounds and methods for treating disease EHMT1, POLRMT, RNASE1 HSP90AA1 2000/4885LMNA 2032/4885MAPT 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.